Signaturefd LLC Raises Stock Holdings in Astera Labs, Inc. $ALAB

Signaturefd LLC raised its position in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 112.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 850 shares of the company’s stock after buying an additional 450 shares during the quarter. Signaturefd LLC’s holdings in Astera Labs were worth $77,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Astera Labs by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 9,297,476 shares of the company’s stock worth $554,780,000 after acquiring an additional 85,846 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Astera Labs by 114.2% during the first quarter. Alliancebernstein L.P. now owns 8,401,019 shares of the company’s stock valued at $501,289,000 after purchasing an additional 4,478,741 shares in the last quarter. Atreides Management LP lifted its holdings in shares of Astera Labs by 153.3% during the first quarter. Atreides Management LP now owns 4,652,264 shares of the company’s stock valued at $277,601,000 after purchasing an additional 2,815,614 shares during the last quarter. Fred Alger Management LLC lifted its holdings in shares of Astera Labs by 13.0% during the first quarter. Fred Alger Management LLC now owns 1,560,033 shares of the company’s stock valued at $93,087,000 after purchasing an additional 179,638 shares during the last quarter. Finally, Altimeter Capital Management LP boosted its position in shares of Astera Labs by 68.0% in the 1st quarter. Altimeter Capital Management LP now owns 981,697 shares of the company’s stock worth $58,578,000 after purchasing an additional 397,267 shares in the last quarter. Institutional investors own 60.47% of the company’s stock.

Insider Activity

In other Astera Labs news, CFO Michael Truett Tate sold 100,000 shares of the business’s stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $171.38, for a total transaction of $17,138,000.00. Following the transaction, the chief financial officer owned 518,996 shares in the company, valued at $88,945,534.48. The trade was a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Manuel Alba sold 183,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $173.27, for a total transaction of $31,708,410.00. Following the completion of the sale, the director directly owned 385,863 shares in the company, valued at approximately $66,858,482.01. This represents a 32.17% decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,492,036 shares of company stock valued at $232,607,552 over the last ninety days. 12.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Jefferies Financial Group raised their price objective on Astera Labs from $95.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, July 22nd. TD Cowen started coverage on Astera Labs in a report on Wednesday, October 1st. They set a “hold” rating and a $200.00 price target for the company. CICC Research began coverage on shares of Astera Labs in a research note on Friday, August 29th. They issued an “outperform” rating and a $190.00 price target on the stock. Citigroup increased their price objective on shares of Astera Labs from $160.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Finally, Northland Capmk cut shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, Astera Labs currently has an average rating of “Moderate Buy” and a consensus price target of $159.83.

Astera Labs Trading Down 4.2%

Shares of NASDAQ:ALAB opened at $200.74 on Monday. The company has a market cap of $33.37 billion, a price-to-earnings ratio of 358.46, a PEG ratio of 5.09 and a beta of 1.43. Astera Labs, Inc. has a 12 month low of $47.13 and a 12 month high of $262.90. The company has a 50-day moving average price of $189.83 and a 200 day moving average price of $119.85.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.11. The business had revenue of $191.93 million for the quarter, compared to the consensus estimate of $172.46 million. Astera Labs had a return on equity of 9.53% and a net margin of 16.54%.The company’s quarterly revenue was up 149.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.13 earnings per share. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, equities analysts forecast that Astera Labs, Inc. will post 0.34 EPS for the current year.

About Astera Labs

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.